"Azabicyclo Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS.
Descriptor ID |
D053961
|
MeSH Number(s) |
D02.145.074 D03.605.084.500
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Azabicyclo Compounds".
Below are MeSH descriptors whose meaning is more specific than "Azabicyclo Compounds".
This graph shows the total number of publications written about "Azabicyclo Compounds" by people in this website by year, and whether "Azabicyclo Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 1 | 0 | 1 |
2017 | 14 | 5 | 19 |
2018 | 19 | 4 | 23 |
2019 | 6 | 2 | 8 |
2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Azabicyclo Compounds" by people in Profiles.
-
Successful Treatment of Klebsiella pneumoniae NDM Sepsis and Intestinal Decolonization with Ceftazidime/Avibactam Plus Aztreonam Combination in a Patient with TTP Complicated by SARSCoV-2 Nosocomial Infection. Medicina (Kaunas). 2021 Apr 28; 57(5).
-
Audio Interview: Covid-19 in South Africa and a New SARS-CoV-2 Variant. N Engl J Med. 2021 Jan 14; 384(2):e14.
-
Efficacy of ceftazidime/avibactam in monotherapy or combination therapy against carbapenem-resistant Gram-negative bacteria: A meta-analysis. Int J Antimicrob Agents. 2019 Dec; 54(6):735-740.
-
Identification of L169P mutation in the omega loop of KPC-3 after a short course of ceftazidime/avibactam. J Antimicrob Chemother. 2019 08 01; 74(8):2466-2467.
-
KPC-31 expressed in a ceftazidime/avibactam-resistant Klebsiella pneumoniae is associated with relevant detection issues. J Antimicrob Chemother. 2019 08 01; 74(8):2464-2466.
-
Reversal of carbapenemase-producing Klebsiella pneumoniae epidemiology from blaKPC- to blaVIM-harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam. J Antimicrob Chemother. 2019 07 01; 74(7):2051-2054.
-
New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. Drugs. 2019 May; 79(7):705-714.
-
In vitro synergistic activity of meropenem/vaborbactam in combination with ceftazidime/avibactam against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2019 05 01; 74(5):1457-1459.
-
In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother. 2019 02 01; 74(2):380-386.
-
Cure of recurring Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae septic shock episodes due to complicated soft tissue infection using a ceftazidime and avibactam-based regimen: a case report. J Med Case Rep. 2019 Jan 22; 13(1):20.